

1 **Medical Costs, Health Care Utilization, and Productivity Losses Associated With**
2 **Hypertension by COVID-19 Among US Commercial Enrollees**

3
4 Jun Soo Lee, PhD¹; Yidan (Xue) Zhang, PhD^{1,2}; Yu Wang, PhD^{3,4}; Joohyun Park, PhD⁵;
5 Ashutosh Kumar, PhD^{1,6}; Bruce Donald, MA^{1,2}; Feijun Luo, PhD^{1*}; Kakoli Roy, PhD^{7*}

6
7 ¹ Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention,
8 Atlanta, Georgia

9 ² ASRT, Inc., Atlanta, Georgia

10 ³ Division of Workforce Development, Centers for Disease Control and Prevention, Atlanta,
11 Georgia

12 ⁴ Data Science and Evaluation Team, American Heart Association, Dallas, Texas

13 ⁵ Division of Drug Overdose Prevention, Centers for Disease Control and Prevention, Atlanta,
14 Georgia

15 ⁶ Bizzell US, New Carrollton, Maryland

16 ⁷ National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease
17 Control and Prevention, Atlanta, Georgia

18
19
20 * Feijun Luo and Kakoli Roy are co-senior authors.

21
22
23 Keywords: hypertension, productivity loss, productivity costs, medical costs, health care
24 utilization, commercial insurance, COVID-19

25
26 Word count: 3,106

27 Abstract: 321; Figures: 1; Tables: 3; eTables: 4; References: 43

28 Corresponding author:

29 Jun Soo Lee, PhD

30 Division for Heart Disease and Stroke Prevention

31 Centers for Disease Control and Prevention

32 4770 Buford Hwy, Building 107

33 Atlanta, GA 30341

34 Tel: 770-488-8978

35 Email: PQA2@cdc.gov

36
37 Disclaimer: The findings and conclusions in this article are those of the authors and do not
38 necessarily represent the official position of the Centers for Disease Control and Prevention. Use
39 of trade names and commercial sources is for identification only and does not imply endorsement
40 by the US Department of Health and Human Services.

41
42 There is no potential conflict of interest related to any part of this article.

44 Sources of funding: The authors received no financial support for the research, authorship,
45 and/or publication of this article.

46
47 Acknowledgements: We thank Michael Schooley, Janet Wright, and Fátima Coronado (Centers
48 for Disease Control and Prevention) for their guidance, suggestions, and manuscript review. We
49 would like to thank Moira Urich (the Centers for Disease Control and Prevention) for review of
50 this manuscript.

51 **Abstract**

52

53 **Background:** Hypertension is a major risk factor for cardiovascular and renal diseases,
54 significantly contributing to morbidity and mortality. The COVID-19 pandemic has heightened
55 concerns about the impact of hypertension on severe COVID-19 outcomes.

56

57 **Methods:** We conducted a cross-sectional analysis using the 2021 MarketScan Commercial and
58 Health and Productivity Management databases. The study included adults aged 18-64 with
59 continuous employer-sponsored private insurance, excluding those with pregnancy or capitated
60 plans. We compared excess total medical costs, healthcare utilization (including the number of
61 emergency department [ED] visits, inpatient admissions, outpatient visits, and outpatient
62 prescription drugs), and productivity losses and related costs due to sick absences, short-term
63 disability (STD), and long-term disability (LTD) between individuals with and without
64 hypertension, further stratified by COVID-19 diagnosis. Multivariate regression models adjusted
65 for demographics and comorbidities were used to estimate the differences in outcomes.

66

67 **Results:** Among 1,612,398 adults aged 18-64 years, 13% had hypertension in 2021. Those with
68 hypertension were older, were less likely to be female or live in urban areas, and exhibited a
69 higher prevalence of comorbidities. The total excess medical costs associated with hypertension
70 were \$8723 per patient (95% CI, \$8352-\$9093), which was significantly higher by \$6117 (95%
71 CI, \$4780-\$7453) among individuals diagnosed with COVID-19. Persons with hypertension had
72 higher health care utilization, including a higher number of ED visits (0.21 per patient; 95% CI,
73 0.21-0.22), inpatient admissions (0.11; 95% CI, 0.10-0.12), outpatient visits (5.42; 95% CI, 5.36-
74 5.49), and outpatient prescription drugs (10.85; 95% CI, 10.75-10.94). Moreover, they
75 experienced a greater number of sick absences (1.22 days; 95% CI, 1.07-1.36) and STD
76 occurrences (3.68 days; 95% CI, 3.38-3.98) per patient compared to those without hypertension.
77 These trends were further exacerbated among individuals diagnosed with COVID-19.

78

79 **Conclusions:** Hypertension markedly increases medical costs, healthcare utilization, and
80 productivity losses, which are further exacerbated by COVID-19. These findings highlight the
81 substantial economic burden of managing hypertension in the context of the COVID-19
82 pandemic and underscore the importance of targeted interventions.

83 INTRODUCTION

84 Hypertension (ie, high blood pressure [BP]) is a major risk factor of cardiovascular and renal
85 diseases, which are among the leading contributors of all-cause mortality.^{1,2} Recent national
86 estimates indicate that approximately 122 million (47%) adults aged 20 years and older have
87 hypertension in the United States (US).^{3,4} Moreover, hypertension has been consistently linked to
88 elevated health care utilization and increased medical cost.⁵⁻⁸ For instance, in 2019, hypertension
89 was implicated in over 18 million hospital discharges, with 1.4 million cases wherein
90 hypertension was the primary diagnosis.^{3,9} The estimated medical cost associated with
91 hypertension was reported to be \$1500 per person per year in 2012-2013, contributing to a
92 staggering \$109 billion (in 2015 US dollars) in total annual medical cost nationwide.⁶

93 In addition to direct medical costs, hypertension is associated with productivity loss
94 among working-age adults.¹⁰ Hypertension often goes unnoticed and remains untreated or
95 uncontrolled, indicating BP levels persistently above the recommended thresholds,¹¹ among
96 working-age adults.¹² For example, 93.4% and 74.4% of hypertensive adults in the US aged 18-
97 44 and 45-64 years had uncontrolled hypertension, respectively, compared with 69.7% of adults
98 aged 65 years and above.¹³ Uncontrolled hypertension is associated with comorbidities that can
99 lead to productivity loss. A systematic literature review of studies published from 1990 through
100 2015 suggests that hypertension-associated absenteeism, presenteeism, and short-term disability
101 cost upwards of \$60, \$70, and \$50 per person per year, respectively, resulting in billions of
102 dollars in total annual productivity loss nationwide (eg, \$11 billion from absenteeism alone).^{10,14-}

103 ¹⁶

104 In parallel, emerging evidence following the onset of the COVID-19 pandemic has
105 pointed to greater morbidity and mortality among COVID-19 patients with comorbid

106 hypertension.¹⁷⁻¹⁹ However, research also indicates that hypertension may independently affect
107 COVID-19 prognosis through heightened immunological activity and organ damage, primarily
108 in those with uncontrolled systolic BP.^{20,21} Compared with peers without hypertension, COVID-
109 19 patients with hypertension are significantly more likely to be hospitalized and require
110 treatment in the intensive care unit.^{17,18} Also, COVID-19 infections may lead to the onset of
111 hypertension in people without preexisting hypertension.²²

112 Despite this growing body of evidence, a significant gap remains in understanding the
113 interaction between hypertension and COVID-19,²³⁻²⁵ especially regarding the impact on medical
114 costs, health care utilization, and productivity losses.²⁶⁻²⁹ To bridge this gap, our study aims to
115 investigate the economic burden of hypertension during the COVID-19 pandemic, specifically
116 focusing on medical costs, health care utilization, and productivity losses among employed
117 adults aged 18-64 years with employer-sponsored private insurance. Additionally, the study
118 seeks to delineate variations in hypertension-related medical costs and productivity losses based
119 on COVID-19 diagnosis status. By addressing these gaps, our study may elucidate the
120 intertwined effects of COVID-19 and hypertension on total medical costs, health care utilization,
121 and productivity loss.

122

123 **METHODS**

124 *Data*

125 We used the MarketScan Commercial and Health and Productivity Management (HPM)
126 databases from 2021.³⁰ The MarketScan Commercial Database contained person-level paid
127 claims and encounters, including medical costs (patients' out-of-pocket costs and insurance
128 payments) and information on health care utilization, such as inpatient services, outpatient
129 services, emergency department (ED) visits, and outpatient prescription drug claims. The data
130 came from approximately 350 payers, encompassing over 20 billion service records provided by
131 >300 employers, >30 health plans, and >500 hospitals nationwide.³⁰ The HPM Database
132 contained detailed payroll-related information about employees, including sick absences, short-
133 term disability (STD), and long-term disability (LTD). All data were de-identified, and the study
134 was exempt from review by the Institutional Review Board of the Centers for Disease Control
135 and Prevention.

136

137 *Identification of Patients With Hypertension*

138 Our sample included employed individuals aged 18-64 years who were continuously enrolled in
139 an employer-sponsored insurance plan throughout 2021. The sample excluded individuals with a
140 pregnancy diagnosis (codes listed in eTable 1) or with capitated insurance in 2021. Finally, we
141 limited the analytic sample to individuals in the HPM Database, who had complete information
142 on absences, STD, or LTD in 2021. Because not all employers provided payroll information, we
143 stratified the sample by individuals with medical cost, sick absence, and STD or LTD
144 information. In each stratified subsample, we identified individuals with hypertension if they had
145 at least 1 inpatient or ED visit or 2 outpatient visits containing a hypertension diagnosis

146 (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] I10
147 through I15) in 2021 (eTable 1).

148

149 ***Outcome Variables***

150 The primary outcome variables, measured in per person per year, are (1) total medical costs (sum
151 of patients' out-of-pocket costs and insurance payments), (2) health care utilization, including the
152 number of ED visits, inpatient admissions, outpatient visits, and outpatient prescription drugs, (3)
153 total missed workdays related to sick absences, STDs, and LTDs, and (4) productivity costs
154 calculated on total missed 8-hour workdays due to sick absences, STDs, and LTDs in 2021.
155 Estimated employer productivity costs were computed by multiplying the number of hours
156 absent from the number of missed workdays times 8 hours, with the average hourly wage in
157 2021.³¹ We adjusted for absences associated with STD (70% of hourly wage) and LTD (60% of
158 hourly wage).^{31,32} The average hourly wage (\$30.61) for all employees in private nonfarm
159 payrolls was obtained from the 2021 US Bureau of Labor Statistics (BLS).³³

160

161 ***Independent Variable***

162 The primary independent variable is a binary variable indicating whether individuals had
163 hypertension in 2021. We interacted this variable with a binary indicator for COVID-19
164 diagnosis (individuals with ICD-10-CM of U07.1 in 2021) to examine the interaction between
165 hypertension and COVID-19 with respect to the outcome variables.

166

167 ***Control Variables***

168 All models were adjusted for age groups (aged 18-34 [reference], 35-44, 45-54, and 55-64
169 years), sex (female [reference], male), residency (rural [reference] and urban),³⁴ census region
170 (Northeast [reference], Midwest, South, and West), and comorbidities. Comorbidities were
171 defined using 17 conditions outlined in the Quan Charlson Comorbidities.³⁵ Each comorbidity
172 was identified if individuals had ≥ 1 inpatient admission or ≥ 2 outpatient encounters (≥ 30 days
173 apart) using the ICD-10-CM diagnosis codes as specified in Quan et al.³⁵

174

175 *Statistical Analysis*

176 We first documented summary statistics of patients' characteristics, including age, sex, rural-
177 urban residence, census region, and comorbidities. We tested the differences in average values
178 by hypertension diagnosis status using the Wilcoxon rank-sum test for continuous variables and
179 Pearson's chi-square test for categorical variables.

180 In the regression analyses, where the dependent variables were total medical costs and
181 productivity costs (related to sick absences, STD, and LTD), we used a generalized linear model
182 (GLM) with a log-link function and gamma distribution. For dependent variables that were count
183 variables, specifically outcomes related to health care utilization (including the number of ED
184 visits, inpatient admissions, and outpatient prescription drugs) and missed workdays (due to sick
185 absences, STD, and LTD), a negative binomial regression model was used. We ran separate
186 regressions for each dependent variable to estimate the association with hypertension status (with
187 and without hypertension) as well as the association including the interaction of hypertension
188 status and COVID-19 diagnosis (with and without COVID-19). The remaining control variables
189 were the same for all models. We reported the predicted outcomes variables in terms of average
190 marginal effects (AMEs) for individuals, both with and without hypertension, and for those with

191 and without COVID-19. Furthermore, we documented the differences in the estimated AMEs by
192 combined hypertension status and by COVID-19 diagnosis status. AMEs represent the change in
193 the predicted outcome variables associated with a one-unit change in the independent variable,
194 holding all other variables constant. AMEs provide estimates of the predicted changes in
195 outcomes resulting from variations in hypertension and COVID-19 diagnosis. We defined the
196 differences in AMEs associated with hypertension and COVID-19 diagnosis status as “excess”
197 outcomes associated with hypertension and COVID-19.

198 In the sensitivity analysis, we applied a zero-inflated negative binomial regression model
199 for the count variables—specifically missed workdays attributable to sick absences, STD, and
200 LTD—and a two-part model for productivity costs due to potential excess zero values in the
201 dependent variables. In the two-part model, we first used a logistic regression to estimate the
202 probability of non-zero expenditures, followed by GLM regression with log-link in the second
203 part.

204 All analyses used 2021 data, which was the most recently available data. Also, there
205 might have been interruptions to medical care during the early COVID-19 pandemic in 2020,^{36,37}
206 as the severity of COVID-19 and its relationship with hypertension might have been different
207 during the early and middle stages of the pandemic. To test this potential interruption, we
208 conducted additional sensitivity analyses using 2020 data. The sensitivity analysis results using
209 2020 were adjusted to 2021 dollars using the Consumer Price Index from the US BLS.³⁸

210 Two-tailed tests with *P* values of <0.05 were used to indicate statistical significance. All
211 analyses were conducted using Stata SE version 17 (StataCorp, College Station, Texas).

212

213 **RESULTS**

214 We identified 1 612 398 employed individuals aged 18-64 years who were continuously enrolled
215 in a noncapitated employer-sponsored private insurance plan without a pregnancy history in
216 2021 (Figure 1). Among these individuals, 139 490 (9%) had non-missing information on
217 workplace absences, 1 355 064 (84%) had non-missing information on STD, and 1 331 963
218 (83%) had non-missing information on LTD. A total of 215 480 (13%) individuals had
219 hypertension in 2021. Persons with hypertension were older (51.2 vs 42.9 years; $P < 0.001$), were
220 less likely to be female (34.0% vs 39.4%; $P < 0.001$), were less likely to reside in urban areas
221 (90.4% vs 92.7%; $P < 0.001$), and had a higher likelihood of having comorbidities ($P < 0.001$ in
222 all comorbidities) (Table 1).

223 Table 2 presents the total adjusted medical costs and health care utilization associated
224 with hypertension, including by COVID-19 diagnosis. The mean total excess medical costs
225 associated with hypertension compared to those without hypertension were \$8723 per patient per
226 year (95% CI, \$8352-\$9093; $P < 0.001$). The total excess medical costs associated with
227 hypertension were significantly higher among persons with COVID-19 than those without
228 COVID-19 (\$14 290 vs \$8173; the difference was \$6117 [95% CI, \$4780-\$7453; $P < 0.001$]).
229 Individuals with hypertension had a higher number of ED visits (0.211 per patient; 95% CI,
230 0.207-0.216; $P < 0.001$), inpatient admissions (0.108; 95% CI, 0.101-0.115; $P < 0.001$),
231 outpatient visits (5.422; 95% CI, 5.357-5.486; $P < 0.001$), and outpatient prescription drugs
232 (10.85; 95% CI, 10.75-10.94; $P < 0.001$) than those without hypertension (Table 2). Compared
233 with adults without COVID-19 diagnosis, those with COVID-19 had a significantly higher
234 number of excess ED visits (0.128; 95% CI, 0.105-0.151; $P < 0.001$), inpatient admission (0.293;
235 95% CI, 0.259-0.328; $P < 0.001$), and outpatient prescription drugs (0.452; 95% CI, 0.132-0.772;
236 $P < 0.001$) associated with hypertension compared to those without hypertension (Table 2).

237 Table 3 documents the productivity losses and costs associated with hypertension by
238 COVID-19 diagnosis. Individuals with hypertension had a higher number of sick absences
239 (1.215 days per patient; 95% CI, 1.068-1.362; $P < 0.001$), STD (3.680; 95% CI, 3.381-3.980;
240 $P < 0.001$), and higher sick absence costs (\$297.3 per patient; 95% CI, \$254.1-\$340.6; $P < 0.001$)
241 and STD costs (\$631.0; 95% CI, \$591.4-\$670.7; $P < 0.001$). Compared with persons without
242 COVID-19 diagnosis, those with COVID-19 had a significantly higher number of excess STD
243 (2.412; 95% CI, 0.837-3.987; $P < 0.01$) and STD costs (\$413.6; 95% CI, \$205.0-\$622.2;
244 $P < 0.001$) associated with hypertension.

245 The sensitivity analyses using a zero-inflated negative binomial and a two-part model are
246 presented in eTable 2. The magnitudes and directions were similar to results from the main
247 analyses, except the number and costs of LTD by COVID-19 diagnosis status became
248 statistically significant.

249 eTables 3 and 4 presented the same results as Tables 2 and 3 using 2020 data. The total
250 medical costs associated with hypertension were \$8961 (95% CI, \$8478-\$9445; $P < 0.001$) in
251 2020 (eTable 3), very similar to the 2021 estimate of \$8723 using 2021 data (Table 2). On the
252 other hand, the differences in total excess medical costs associated with hypertension by
253 COVID-19 diagnosis status were much higher in 2020 estimates (\$18 167; 95% CI, \$14 320-
254 \$22 014; $P < 0.001$) than 2021 estimates (\$6117; 95% CI, 4780-7453) (Table 2). The differences
255 in excess inpatient admission associated with hypertension by COVID-19 diagnosis status were
256 0.986 per patient (95% CI, 0.825-1.147; $P < 0.001$) (eTable 3), more than 3 times higher than the
257 0.293 estimate using 2021 data (Table 2). Similarly, the differences in the number of excess ED
258 visits and outpatient prescription drugs were higher in 2020 than in 2021. The estimated

259 differences of excess productivity losses, and costs associated with hypertension by COVID-19
260 diagnosis in 2020 (eTable 4), were similar to estimates in 2021.

261

262 **DISCUSSION**

263 This is the first study to assess the excess medical costs, health care utilization, and productivity-
264 related outcomes and costs associated with hypertension by COVID-19 diagnosis. In 2021,
265 adults aged 18-64 years with employer-sponsored private insurance experienced an estimated
266 excess medical cost of \$8723 per patient associated with hypertension. Meanwhile, the combined
267 productivity loss attributable to hypertension resulting from sick absences and STD was \$928 per
268 patient. Furthermore, patients with hypertension who had a COVID-19 diagnosis exhibited
269 significantly higher medical costs compared to those without COVID-19. Overall, the excess
270 medical cost associated with hypertension was \$6117 higher for individuals with a COVID-19
271 diagnosis in comparison to those without a COVID-19 diagnosis. Furthermore, a COVID-19
272 diagnosis was associated with a \$414 increase in hypertension-associated excess STD-related
273 costs, whereas sick absences and LTD-related productivity losses were not significantly different
274 for persons with and without COVID-19. The higher medical cost associated with hypertension
275 among patients with a COVID-19 diagnosis was primarily driven by increased ED visits,
276 inpatient admissions, and outpatient prescription drugs.

277 Given the interdependent relationship between hypertension and COVID-19 in our
278 regression models, our findings can also be interpreted as excess costs, utilization and
279 productivity losses associated with COVID-19 diagnosis among individuals with and without
280 hypertension. For instance, total medical costs associated with COVID-19 can be interpreted as
281 being significantly higher among persons with hypertension compared to those without.

282 Similarly, other health care utilization and productivity outcomes indicated considerably higher
283 associations with COVID-19 diagnosis among individuals with hypertension compared to those
284 without.

285 Our findings are consistent with prior research, indicating elevated number of ED visits,
286 inpatient and outpatient treatment, and medication use among adults with hypertension compared
287 to those without.^{5,6} However, our estimated medical cost associated with hypertension (\$8723
288 per patient per year) significantly surpasses prepandemic estimates derived from national
289 household surveys, which were typically \$1500-\$2500 per person annually.⁵⁻⁷ Several factors
290 may underlie these discrepancies. First, the focus of our study on the COVID-19 period may
291 inherently differ from prepandemic studies, in terms of health care utilization and medical costs.
292 Second, our study may differ from prior research that encompassed individuals across various
293 insurance types. This difference may explain variations in costs between privately insured
294 employed adults in our study, and previous studies' populations, which likely also included those
295 covered by public insurance as well as uninsured population. Third, previous studies using
296 survey data identified individuals with lifetime hypertension, whereas our analysis, based on
297 claims databases, focused on individuals diagnosed with hypertension within the study year.
298 Adults with documented lifetime hypertension in survey databases may have received ongoing
299 management and control for their condition, potentially resulting in lower recorded hypertension-
300 related medical costs compared to those diagnosed within our study sample. And fourth, our
301 stringent criteria for identifying individuals with hypertension—requiring them to have at least 1
302 inpatient admission or 2 outpatient visits with a hypertension diagnosis—might have
303 inadvertently excluded individuals with less severe hypertension.

304 Preexisting hypertension may increase the risk of severe COVID-19 symptoms; likewise,
305 COVID-19 may be associated with subsequent onset or exacerbation of hypertension.^{20-22,39} For
306 example, existing evidence has linked hypertension with increased hyperinflammatory responses
307 following a SARS-CoV-19 infection, which may contribute to a more severe trajectory of
308 COVID-19.²⁰ In a study involving more than 5500 inpatients with COVID-19 who had no
309 history of hypertension, 21% developed new-onset hypertension during hospitalization.²² The
310 potential correlation between hypertension and more severe COVID-19 symptoms may in part
311 explain our findings that hypertension-related health care utilization and costs are higher among
312 persons with a COVID-19 diagnosis.^{24,40}

313 Also, in our sensitivity analysis, we observed significantly higher medical costs associated
314 with hypertension among those diagnosed with COVID-19 in 2020 compared to 2021. The
315 introduction of mRNA-based COVID-19 vaccines, proven safe and effective for individuals with
316 hypertension,⁴¹ might have played a role in the reduction of hypertension-related medical costs in
317 2021 vs 2020.⁴² Further exploration may be required to understand the temporal impact of
318 vaccination on hypertension disease severity and medical costs. Understanding the evolving
319 dynamics between COVID-19 disease management, vaccination programs, and associated
320 medical costs—especially among those with poor baseline health and/or comorbidities like
321 hypertension—may help assess the broader implications of COVID-19 interventions on health
322 care costs and outcomes.

323 Lastly, prior research has consistently demonstrated the substantial impact of hypertension
324 on productivity, contributing to increased work absences, compromised on-the-job productivity,
325 and heightened disabilities.¹⁰ Our study further contributes to this literature by unveiling the
326 compounded effect of a COVID-19 diagnosis on productivity losses associated with

327 hypertension. This finding illuminates the intricate interplay between COVID-19 and
328 hypertension, encouraging a reevaluation of the broader economic repercussions of the
329 pandemic. In this context, it becomes crucial for future investigations to not only account for the
330 direct medical and productivity costs linked to COVID-19 treatment but also to consider the
331 additional economic burden in managing concurrent chronic conditions such as hypertension.
332 Understanding and addressing these intertwined health care challenges are pivotal for devising
333 comprehensive strategies aimed at mitigating the multidimensional impacts of global health
334 crises, exemplified by the ongoing challenges posed by COVID-19.

335

336 **Limitation**

337 This study is subject to several limitations. First, the MarketScan Commercial Database,
338 sourced from large employers, represents a convenience sample, limiting the generalizability of
339 findings to privately insured individuals with payroll information. Consequently, the study
340 findings cannot be generalized to the broader spectrum of privately insured US adults. Second,
341 the findings might not accurately represent individuals lacking health insurance or covered by
342 public insurance programs like Medicare and Medicaid. Notably, one of our primary outcomes—
343 productivity losses—is contingent upon data from employers' payroll systems, thereby excluding
344 persons without employment or those covered by public insurance. Third, our study focused
345 solely on surviving individuals with hypertension and COVID-19, precluding the assessment of
346 costs and productivity due to mortality. Fourth, we were unable to ascertain the severity levels of
347 hypertension and COVID-19, which could have distinct effects on the outcomes, potentially
348 leading to an underestimation of our results. Lastly, while emerging evidence links hypertension
349 with an elevated risk of Long COVID symptoms,⁴³ our cross-sectional data precluded an

350 evaluation of the longitudinal impact of a COVID-19 diagnosis on hypertension-related health
351 care utilization and economic costs.

352

353 **CONCLUSIONS**

354 The economic burden of hypertension, in terms of medical costs and productivity loss, is
355 substantial. Our study reveals that individuals diagnosed with COVID-19 incurred even higher
356 excess medical costs, health care utilization, and productivity losses attributable to hypertension.
357 These findings emphasize the importance of factoring in costs of chronic comorbidities in
358 assessing the overall economic burden of COVID-19. These estimates can help assess the
359 economic impact (eg, costs averted) of interventions effective in preventing COVID-19 among
360 individuals with preexisting hypertension.


REFERENCES

1. Aune D, Huang W, Nie J, Wang Y. Hypertension and the risk of all-cause and cause-specific mortality: an outcome-wide association study of 67 causes of death in the National Health Interview Survey. *BioMed Research International*. 2021;2021
2. Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. *NCHS Data Brief*. Dec 2022;(456):1-8.
3. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147(8):e93-e621. doi:doi:10.1161/CIR.0000000000001123
4. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). Data from: National Health and Nutrition Examination Survey Data, 2017-2020. 2020. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
5. Kirkland EB, Heincelman M, Bishu KG, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. *Journal of the American Heart Association*. 2018;7(11):e008731.
6. Zhang D, Wang G, Zhang P, Fang J, Ayala C. Medical expenditures associated with hypertension in the US, 2000–2013. *American journal of preventive medicine*. 2017;53(6):S164-S171.
7. Wang G, Zhou X, Zhuo X, Zhang P. Annual total medical expenditures associated with hypertension by diabetes status in US adults. *American journal of preventive medicine*. 2017;53(6):S182-S189.
8. Mitchell EM. Concentration of healthcare expenditures and selected characteristics of persons with high expenses, U.S. Civilian Noninstitutionalized Population, 2020. *Statistical Brief (Medical Expenditure Panel Survey (US))*. Agency for Healthcare Research and Quality (US); 2023.
9. Data from: HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2019. Agency for Healthcare Research and Quality, Rockville, MD.
10. MacLeod KE, Ye Z, Donald B, Wang G. A literature review of productivity loss associated with hypertension in the United States. *Population Health Management*. 2022;25(3):297-308.
11. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2018;71(19):e127-e248.
12. Wall HK, Hannan JA, Wright JS. Patients with undiagnosed hypertension: hiding in plain sight. *JAMA*. 2014;312(19):1973-1974. doi:10.1001/jama.2014.15388
13. Centers for Disease Control and Prevention (CDC). Division of Heart Disease and Stroke Prevention. Estimated Hypertension Prevalence, Treatment, and Control Among U.S. Adults. Accessed November 1, 2023. <https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html>
14. Henke RM, Carls GS, Short ME, et al. The relationship between health risks and health and productivity costs among employees at Pepsi Bottling Group. *Journal of occupational and environmental medicine*. 2010:519-527.

15. Kowlessar NM, Goetzel RZ, Carls GS, Tabrizi MJ, Guindon A. The relationship between 11 health risks and medical and productivity costs for a large employer. *Journal of occupational and environmental medicine*. 2011;468-477.
16. Kirkham HS, Clark BL, Bolas CA, et al. Which modifiable health risks are associated with changes in productivity costs? *Population Health Management*. 2015;18(1):30-38.
17. Ebinger JE, Driver M, Joung S, et al. Hypertension and excess risk for severe COVID-19 illness despite booster vaccination. *Hypertension*. 2022;79(10):e132-e134.
18. Chen J, Liu Y, Qin J, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. *Postgraduate medical journal*. 2022;98(1161):515-522.
19. World Health Organization. (2021). *Hypertension and COVID-19: scientific brief, 17 June 2021*. World Health Organization. <https://iris.who.int/bitstream/handle/10665/341848/WHO-2019-nCoV-Sci-Brief-Hypertension-2021.1-eng.pdf>.
20. Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nature biotechnology*. 2021;39(6):705-716.
21. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current evidence and perspectives. *High Blood Pressure & Cardiovascular Prevention*. 2022;29(2):115-123.
22. Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of New-Onset Hypertension Post-COVID-19: Comparison With Influenza. *Hypertension*. 2023;80(10):2135-2148. doi:doi:10.1161/HYPERTENSIONAHA.123.21174
23. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. *Nutrition, Metabolism and Cardiovascular Diseases*. 2021;31(3):745-755.
24. Peng M, He J, Xue Y, Yang X, Liu S, Gong Z. Role of Hypertension on the Severity of COVID-19: A Review. *Journal of cardiovascular pharmacology*. 2021;78(5):e648.
25. Batiha GE-S, Gari A, Elshony N, et al. Hypertension and its management in COVID-19 patients: The assorted view. *International Journal of Cardiology Cardiovascular Risk and Prevention*. 2021;11:200121.
26. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. *Annals of Internal Medicine*. 2021/04/20 2020;174(4):576-578. doi:10.7326/M20-5661
27. Ohsfeldt RL, Choong CK-C, Mc Collam PL, Abedtash H, Kelton KA, Burge R. Inpatient Hospital Costs for COVID-19 Patients in the United States. *Advances in Therapy*. 2021/11/01 2021;38(11):5557-5595. doi:10.1007/s12325-021-01887-4
28. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. *Journal of Medical Economics*. 2021/01/01 2021;24(1):308-317. doi:10.1080/13696998.2021.1886109
29. Lee JS, Lowe Beasley K, Schooley MW, Luo F. Trends and Costs of US Telehealth Use Among Patients With Cardiovascular Disease Before and During the COVID-19 Pandemic. *Journal of the American Heart Association*. 2023;12(4):e028713.
30. Data from: Truven Health MarketScan® Research Databases. <https://marketscan.truvenhealth.com/marketscanportal> Accessed March 9, 2023.

31. Park J, Bigman E, Zhang P. Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18–64 Years With Large Employer-Sponsored Insurance. *Diabetes care*. 2022;45(11):2553-2560.
32. Settupane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. *Annals of Allergy, Asthma & Immunology*. 2019;123(6):564-572. e3.
33. U.S. Bureau of Labor Statistics, Average Hourly Earnings of All Employees, Total Private [CES0500000003], retrieved from FRED, Federal Reserve Bank of St. Louis; <https://fred.stlouisfed.org/series/CES0500000003>, October 3, 2023.
34. Ingram DD, Franco SJ. *2013 NCHS urban-rural classification scheme for counties*. US Department of Health and Human Services, Centers for Disease Control and ...; 2014.
35. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical care*. 2005;1130-1139.
36. Papautsky EL, Rice DR, Ghoneima H, et al. Characterizing health care delays and interruptions in the United States during the COVID-19 pandemic: internet-based, cross-sectional survey study. *Journal of medical Internet research*. 2021;23(5):e25446.
37. Czeisler MÉ, Marynak K, Clarke KE, et al. Delay or avoidance of medical care because of COVID-19–related concerns—United States, June 2020. *Morbidity and mortality weekly report*. 2020;69(36):1250.
38. U.S. Bureau of Labor Statistics, Consumer Price Index for All Urban Consumers: All Items in U.S. City Average [CPIAUCSL], retrieved from FRED, Federal Reserve Bank of St. Louis; <https://fred.stlouisfed.org/series/CPIAUCSL>, October 3, 2023.
39. Delalić Đ, Jug J, Prkačin I. ARTERIAL HYPERTENSION FOLLOWING COVID-19: A RETROSPECTIVE STUDY OF PATIENTS IN A CENTRAL EUROPEAN TERTIARY CARE CENTER. *Acta Clin Croat*. Jun 2022;61(Suppl 1):23-27. doi:10.20471/acc.2022.61.s1.03
40. Scott A, Ansari W, Khan F, et al. Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19. *BMC Medicine*. 2024/02/01 2024;22(1):46. doi:10.1186/s12916-023-03234-6
41. Shibata S, Kobayashi K, Tanaka M, et al. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. *Hypertension Research*. 2023/03/01 2023;46(3):589-600. doi:10.1038/s41440-022-01134-5
42. Centers for Disease Control and Prevention (CDC). CDC Museum COVID-19 Timeline. Accessed November 1, 2023. <https://www.cdc.gov/museum/timeline/covid19.html>
43. Song Z, Giuriato M. Demographic And Clinical Factors Associated With Long COVID: Study examines demographic and clinical factors associated with long COVID among people who suffer symptoms long after they were first diagnosed with COVID-19 (long haulers). *Health Affairs*. 2023;42(3):433-442.

Figure 1. Study Sample Selection of Patients Diagnosed With Hypertension, MarketScan® Commercial and Health and Productivity Management Database, 2021



Abbreviations: HPM, Health and Productivity Management; LTD, long-term disability; STD, short-term disability.

43 **Table 1.** Summary Statistics, MarketScan® Commercial Insurance, 2021^a

	All	Without hypertension	With hypertension
	N = 1 612 398	N = 1 396 918	N = 215 480
Age, mean (SD)	44.0 (11.1)	42.9 (11.0)	51.2 (8.5) ^{***}
Age groups, n (%)			
18-34	394 617 (24.47%)	383 744 (27.47%)	10 873 (5.05%) ^{***}
35-44	411 201 (25.50%)	376 307 (26.94%)	34 894 (16.19%) ^{***}
45-54	451 159 (27.98%)	372 585 (26.67%)	78 574 (36.46%) ^{***}
55-64	355 421 (22.04%)	264 282 (18.92%)	91 139 (42.30%) ^{***}
Female, n (%)	623 335 (38.66%)	550 081 (39.38%)	73 254 (34.00%) ^{***}
Urban residency, n (%)	1 489 709 (92.39%)	1 294 879 (92.70%)	194 830 (90.42%) ^{***}
Census regions, n (%)			
Northeast	239 802 (14.87%)	211 483 (15.14%)	28 319 (13.14%) ^{***}
Midwest	387 301 (24.02%)	334 612 (23.95%)	52 689 (24.45%) ^{***}
South	694 461 (43.07%)	585 403 (41.91%)	109 058 (50.61%) ^{***}
West	283 790 (17.60%)	259 426 (18.57%)	24 364 (11.31%) ^{***}
COVID-19 diagnosis, n (%)	144 896 (8.99%)	118 940 (8.51%)	25 956 (12.05%) ^{***}
Comorbidities, n (%)			
Myocardial infarction	8 243 (0.51%)	2 901 (0.21%)	5342 (2.48%) ^{***}
Congestive heart failure	8648 (0.54%)	2378 (0.17%)	6270 (2.91%) ^{***}
Peripheral vascular disease	7538 (0.47%)	2959 (0.21%)	4579 (2.13%) ^{***}
Cerebrovascular disease	2538 (0.16%)	944 (0.07%)	1594 (0.74%) ^{***}
Dementia	119 (0.01%)	56 (0.00%)	63 (0.03%) ^{***}
Chronic pulmonary disease	36 105 (2.24%)	24 416 (1.75%)	11 689 (5.42%) ^{***}
Rheumatic disease	9912 (0.61%)	7154 (0.51%)	2758 (1.28%) ^{***}
Peptic ulcer disease	1322 (0.08%)	767 (0.05%)	555 (0.26%) ^{***}
Mild liver disease	14 064 (0.87%)	8241 (0.59%)	5823 (2.70%) ^{***}
Diabetes without chronic complication	91 093 (5.65%)	41 273 (2.95%)	49 820 (23.12%) ^{***}
Diabetes with chronic complication	18 362 (1.14%)	6706 (0.48%)	11 656 (5.41%) ^{***}
Hemiplegia or paraplegia	1284 (0.08%)	554 (0.04%)	730 (0.34%) ^{***}
Renal disease	10 807 (0.67%)	2459 (0.18%)	8348 (3.87%) ^{***}
Any malignancy	25 244 (1.57%)	17 617 (1.26%)	7627 (3.54%) ^{***}
Moderate or severe liver disease	767 (0.05%)	372 (0.03%)	395 (0.18%) ^{***}
Metastatic solid tumor	3396 (0.21%)	2212 (0.16%)	1184 (0.55%) ^{***}
AIDS/HIV	3447 (0.21%)	2527 (0.18%)	920 (0.43%) ^{***}

44

45 Abbreviations: SD, standard deviation.

46 ^a We used the Wilcoxon nonparametric rank-sum test to test the differences in means for continuous variables, and
 47 the Pearson's chi-square test to test differences in proportions for categorical variables by medication nonadherence
 48 to antihypertensive drug status. *** $P < 0.001$

49 **Table 2.** Total Medical Costs and Health Care Utilization Associated With Hypertension, 2021^a

	All	Without COVID-19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Total medical costs, \$				
Without hypertension	9056	8228	17 446	9219***
	(8724 to 9387)	(7945 to 8510)	(16 518 to 18 374)	(8519 to 9918)
With hypertension	17 779	16 401	31 736	15 335***
	(17 131 to 18 426)	(15 830 to 16 971)	(29 801 to 33 671)	(13 718 to 16 952)
Difference ^b	8723***	8173***	14 290***	6117***
	(8352 to 9093)	(7831 to 8515)	(12 888 to 15 691)	(4780 to 7453)
Observations	1 612 398	1 467 502	144 896	1 612 398
Health care utilization				
Number of emergency department visits				
Without hypertension	0.176	0.148	0.461	0.313***
	(0.175 to 0.177)	(0.147 to 0.149)	(0.454 to 0.468)	(0.306 to 0.320)
With hypertension	0.388	0.348	0.789	0.441***
	(0.383 to 0.392)	(0.344 to 0.352)	(0.767 to 0.811)	(0.419 to 0.463)
Difference ^b	0.211***	0.200***	0.328***	0.128***
	(0.207 to 0.216)	(0.195 to 0.204)	(0.305 to 0.351)	(0.105 to 0.151)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of inpatient admissions				
Without hypertension	0.0476	0.0297	0.229	0.199***
	(0.0443 to 0.0508)	(0.0280 to 0.0313)	(0.208 to 0.249)	(0.180 to 0.218)
With hypertension	0.156	0.111	0.604	0.492***
	(0.146 to 0.165)	(0.105 to 0.117)	(0.549 to 0.658)	(0.442 to 0.542)
Difference ^b	0.108***	0.0817***	0.375***	0.293***
	(0.101 to 0.115)	(0.0772 to 0.0861)	(0.337 to 0.413)	(0.259 to 0.328)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of outpatient visits				
Without hypertension	8.522	8.223	11.55	3.329***
	(8.505 to 8.539)	(8.207 to 8.240)	(11.48 to 11.62)	(3.260 to 3.399)
With hypertension	13.94	13.66	16.81	3.151***
	(13.88 to 14.01)	(13.60 to 13.73)	(16.61 to 17.02)	(2.937 to 3.365)
Difference ^b	5.422***	5.438***	5.260***	-0.178
	(5.357 to 5.486)	(5.370 to 5.505)	(5.043 to 5.477)	(-0.402 to 0.0467)
Observations	1 612 398	1 467 502	144 896	1 612 398
Number of outpatient prescription drugs				
Without hypertension	9.824	9.596	12.13	2.536***
	(9.802 to 9.845)	(9.574 to 9.617)	(12.05 to 12.21)	(2.459 to 2.613)
With hypertension	20.67	20.40	23.39	2.988***
	(20.58 to 20.76)	(20.31 to 20.50)	(23.09 to 23.69)	(2.677 to 3.299)
Difference ^b	10.85***	10.81***	11.26***	0.452**
	(10.75 to 10.94)	(10.71 to 10.91)	(10.95 to 11.57)	(0.132 to 0.772)
Observations	1 612 398	1 467 502	144 896	1 612 398

50
51

*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$.

52 ^a We used a generalized linear model for total medical costs and a negative binomial model for the number of
53 emergency department visits, inpatient admissions, outpatient visits, and outpatient prescription drugs. All estimates
54 were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of
55 residence, Census regions, and comorbidities.

56
57 ^b The differences in the predicted values, ie, average marginal effects associated with hypertension.
58

Table 3. Productivity Losses and Costs Associated With Hypertension, 2021^a

	All	Without COVID-19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick Absences (days)				
Without hypertension	2.181	1.990	3.870	1.880***
	(2.137 to 2.225)	(1.950 to 2.031)	(3.658 to 4.081)	(1.668 to 2.091)
With hypertension	3.396	3.220	4.952	1.732***
	(3.255 to 3.536)	(3.078 to 3.361)	(4.426 to 5.478)	(1.193 to 2.270)
Difference ^b	1.215***	1.230***	1.082***	-0.148
	(1.068 to 1.362)	(1.083 to 1.377)	(0.514 to 1.650)	(-0.727 to 0.431)
Observations	139 490	125 345	14 145	139 490
STD (days)				
Without hypertension	2.736	2.349	6.699	4.351***
	(2.628 to 2.844)	(2.262 to 2.435)	(6.212 to 7.186)	(3.903 to 4.799)
With hypertension	6.416	5.815	12.58	6.763***
	(6.082 to 6.750)	(5.506 to 6.123)	(10.99 to 14.16)	(5.195 to 8.331)
Difference ^b	3.680***	3.466***	5.878***	2.412**
	(3.381 to 3.980)	(3.184 to 3.748)	(4.312 to 7.444)	(0.837 to 3.987)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD (days)				
Without hypertension	0.842	0.703	2.236	1.533
	(-1.676 to 3.361)	(-1.330 to 2.736)	(-5.617 to 10.09)	(-4.508 to 7.574)
With hypertension	2.470	1.996	7.216	5.220
	(-4.927 to 9.866)	(-3.764 to 7.757)	(-18.31 to 32.75)	(-15.26 to 25.70)
Difference ^b	1.627	1.293	4.980	3.687
	(-3.268 to 6.522)	(-2.449 to 5.034)	(-12.93 to 22.89)	(-11.04 to 18.41)
Observations	1 331 963	1 211 127	120 836	1 331 963
Productivity associated costs^c				
Sick absence costs, \$				
Without hypertension	534.0	487.3	947.5	460.2***
	(521.0 to 547.0)	(475.4 to 499.2)	(885.2 to 1010)	(397.9 to 522.5)
With hypertension	831.3	788.4	1212	423.8***
	(790.1 to 872.5)	(746.8 to 829.9)	(1056 to 1368)	(264.3 to 583.3)
Difference ^b	297.3***	301.0***	264.6**	-36.43
	(254.1 to 340.6)	(257.9 to 344.2)	(96.50 to 432.7)	(-207.7 to 134.9)
Observations	139 490	125 345	14 145	139 490
STD costs, \$				
Without hypertension	469.0	402.6	1149	746.0***
	(454.6 to 483.3)	(391.2 to 414.1)	(1084 to 1213)	(686.7 to 805.3)
With hypertension	1100	996.9	2156	1160***
	(1056 to 1144)	(956.0 to 1038)	(1946 to 2367)	(951.8 to 1367)
Difference ^b	631.0***	594.2***	1008***	413.6***
	(591.4 to 670.7)	(556.9 to 631.6)	(800.3 to 1215)	(205.0 to 622.2)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD costs, \$				
Without hypertension	123.8	103.4	328.8	225.4
	(-190.4 to 438.1)	(-150.3 to 357.1)	(-650.8 to 1308)	(-527.9 to 978.7)
With hypertension	363.1	293.5	1061	767.7
	(-559.8 to 1286)	(-425.3 to 1012)	(-2124 to 4246)	(-1787 to 3322)
Difference ^b	239.3	190.1	732.4	542.3

	(-371.5 to 850.1)	(-276.8 to 657.0)	(-1,502 to 2,967)	(-1,294 to 2,379)
Observations	1 331 963	1 211 127	120 836	1 331 963

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** p<0.001, ** p<0.01, * p<0.05

^a A negative binomial model was used for the number of sick absences, STD, and LTD. A generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2021. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.

Supplemental Materials

eTable 1. The ICD-10-CM for Hypertension and ICD-10-CM, DRG, and ICD-10-PCS Procedure Codes Used for Pregnancy Exclusion

	ICD-10-CM	DRG	ICD-10-PCS Procedure
Hypertension	I10-I15	NA	NA
Pregnancy	O00-O99, O9A1-O9A5, Z33, Z34, Z36, Z37, Z3201, Z322, Z39, F53, A34	765, 766, 767, 768, 769, 770, 771, 772, 773, 775, 776, 777, 779, 780, 781, 782	10A0, 10D00Z0, 10D00Z1, 10D00Z2, 10D07Z3, 10D07Z4, 10D07Z5, 10D07Z6, 10D07Z7, 10D07Z8, 10E0XZZ

Abbreviations: CM, clinical modification; DRG, diagnosis-related group; ICD, International Classification of Diseases; NA, not available; PCS, procedure coding system.

eTable 2. Productivity Losses and Costs Associated With Hypertension Using a Zero-Inflated Negative Binomial and a Two-Part Model, 2021^a

	All	Without COVID-19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick absences (days)				
Without hypertension	2.163 (2.114 to 2.212)	2.028 (1.979 to 2.076)	3.360 (3.200 to 3.520)	1.332*** (1.173 to 1.492)
With hypertension	3.180 (3.018 to 3.342)	3.069 (2.898 to 3.240)	4.163 (3.775 to 4.550)	1.094*** (0.685 to 1.503)
Difference ^b	1.017*** (0.845 to 1.190)	1.041*** (0.860 to 1.223)	0.803*** (0.387 to 1.219)	-0.239 (-0.676 to 0.199)
Observations	139 490	125 345	14 145	139 490
STD (days)				
Without hypertension	2.958 (2.924 to 2.993)	3.015 (2.978 to 3.051)	2.381 (2.331 to 2.432)	-0.633*** (-0.691 to -0.576)
With hypertension	3.398 (3.337 to 3.459)	3.424 (3.359 to 3.488)	3.130 (3.032 to 3.229)	-0.293*** (-0.400 to -0.187)
Difference ^b	0.439*** (0.375 to 0.504)	0.409*** (0.340 to 0.478)	0.749*** (0.641 to 0.857)	0.340*** (0.219 to 0.461)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD (days)				
Without hypertension	0.456 (0.426 to 0.486)	0.459 (0.427 to 0.491)	0.427 (0.384 to 0.470)	-0.0318 (-0.0803 to 0.0167)
With hypertension	0.469 (0.440 to 0.498)	0.464 (0.435 to 0.493)	0.514 (0.448 to 0.581)	0.0504 (-0.0155 to 0.116)
Difference ^b	0.0125 (-0.0206 to 0.0456)	0.00508 (-0.0303 to 0.0404)	0.0873* (0.0122 to 0.162)	0.0822* (0.000322 to 0.164)
Observations	1 331 963	1 211 127	120 836	1 331 963
Productivity associated costs^c				
Sick absence costs, \$				
Without hypertension	533.9 (522.0 to 545.9)	488.1 (476.6 to 499.6)	940.0 (887.8 to 992.2)	451.9*** (399.4 to 504.5)
With hypertension	826.4 (788.9 to 863.8)	783.6 (745.2 to 822.0)	1205 (1077 to 1333)	421.4*** (290.0 to 552.9)
Difference ^b	292.4*** (252.5 to 332.3)	295.5*** (255.0 to 336.0)	265.0*** (126.4 to 403.7)	-30.50 (-172.2 to 111.2)
Observations	139 490	125 345	14 145	139 490
STD costs, \$				
Without hypertension	444.6 (439.2 to 450.0)	390.6 (385.3 to 396.0)	997.6 (974.4 to 1021)	607.0*** (583.4 to 630.6)
With hypertension	1014 (992.5 to 1035)	931.4 (909.7 to 953.1)	1857 (1785 to 1930)	926.0*** (852.3 to 999.8)
Difference ^b	569.2*** (546.7 to 591.7)	540.8*** (518.0 to 563.6)	859.9*** (783.3 to 936.4)	319.1*** (241.5 to 396.6)
Observations	1 355 064	1 234 579	120 485	1 355 064
LTD costs, \$				
Without hypertension	52.72 (49.19 to 56.24)	48.97 (45.47 to 52.47)	90.28 (75.28 to 105.3)	41.30*** (26.09 to 56.52)
With hypertension	133.2	123.2	232.8	109.6***

	(121.4 to 144.9)	(111.4 to 135.1)	(189.7 to 275.9)	(65.82 to 153.3)
Difference ^b	80.47***	74.28***	142.5***	68.25**
	(67.74 to 93.19)	(61.58 to 86.98)	(96.45 to 188.6)	(21.88 to 114.6)
Observations	1 331 963	1 211 127	120 836	1 331 963

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$

^a This table provides the same dependent variables with Table 3 but with different models for robustness check. A zero-inflated negative binomial model was used for number of sick absences, STD, and LTD. A two-part model was used, where the first part is a logistic regression model, and the second part is a generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2021. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.

eTable 3. Supplementary Analysis Using 2020 Data—Total Medical Costs and Health Care Utilization Associated With Hypertension^a

	All	Without COVID-19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Total medical costs, \$				
Without hypertension	9505 (9042 to 9969)	8507 (8168 to 8847)	28 984 (25 901 to 32 068)	20 477*** (17 698 to 23 256)
With hypertension	18 467 (17 573 to 19 360)	16 583 (15 916 to 17 250)	55 227 (48 912 to 61 542)	38 644*** (32 828 to 44 460)
Difference ^b	8961*** (8478 to 9445)	8076*** (7695 to 8457)	26 243*** (22 237 to 30 249)	18 167*** (14 320 to 22 014)
Observations	1 748 789	1 663 548	85 241	1 748 789
Health care utilization				
Number of emergency department visits				
Without hypertension	0.171 (0.170 to 0.172)	0.157 (0.156 to 0.158)	0.445 (0.437 to 0.454)	0.289*** (0.280 to 0.297)
With hypertension	0.388 (0.384 to 0.392)	0.365 (0.361 to 0.370)	0.829 (0.799 to 0.859)	0.464*** (0.434 to 0.494)
Difference ^b	0.217*** (0.213 to 0.222)	0.209*** (0.204 to 0.213)	0.384*** (0.353 to 0.415)	0.175*** (0.144 to 0.207)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of inpatient admissions				
Without hypertension	0.0573 (0.0515 to 0.0630)	0.0337 (0.0314 to 0.0360)	0.518 (0.442 to 0.594)	0.485*** (0.410 to 0.559)
With hypertension	0.203 (0.184 to 0.222)	0.131 (0.123 to 0.140)	1.602 (1.368 to 1.837)	1.471*** (1.244 to 1.698)
Difference ^b	0.146*** (0.133 to 0.159)	0.0978*** (0.0915 to 0.104)	1.084*** (0.918 to 1.250)	0.986*** (0.825 to 1.147)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of outpatient visits				
Without hypertension	7.600 (7.585 to 7.615)	7.441 (7.426 to 7.456)	10.70 (10.62 to 10.79)	3.261*** (3.176 to 3.346)
With hypertension	12.56 (12.50 to 12.61)	12.40 (12.35 to 12.46)	15.64 (15.39 to 15.89)	3.240*** (2.983 to 3.497)
Difference ^b	4.960*** (4.902 to 5.017)	4.961*** (4.902 to 5.019)	4.940*** (4.674 to 5.205)	-0.0208 (-0.291 to 0.249)
Observations	1 748 789	1 663 548	85 241	1 748 789
Number of outpatient prescription drugs				
Without hypertension	9.783 (9.760 to 9.806)	9.655 (9.632 to 9.678)	12.28 (12.17 to 12.39)	2.626*** (2.515 to 2.737)
With hypertension	21.01 (20.90 to 21.11)	20.84 (20.73 to 20.94)	24.31 (23.87 to 24.75)	3.475*** (3.020 to 3.929)
Difference ^b	11.22*** (11.12 to 11.33)	11.18*** (11.07 to 11.29)	12.03*** (11.57 to 12.49)	0.849*** (0.382 to 1.316)
Observations	1 748 789	1 663 548	85 241	1 748 789

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** $pP < 0.001$, ** $P < 0.01$, * $P < 0.05$.

^a We used a generalized linear model for total medical costs and a negative binomial model for the number of emergency department visits, outpatient visits, and outpatient prescription drugs. For inpatient admissions, we used a zero-inflated negative binomial model to account for excess zeros. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities. All costs were adjusted to 2021 dollars using the Consumer Price Index from the US Bureau of Labor Statistics.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

eTable 4. Supplementary Analysis Using 2020 Data—Productivity Losses and Costs Associated With Hypertension^a

	All	Without COVID-19 diagnosis	With COVID-19 diagnosis	With COVID-19 vs without COVID-19
Sick absences (days)				
Without hypertension	1.843	1.790	2.780	0.990***
	(1.817 to 1.869)	(1.765 to 1.815)	(2.626 to 2.934)	(0.836 to 1.144)
With hypertension	2.704	2.639	3.841	1.202***
	(2.621 to 2.786)	(2.555 to 2.723)	(3.437 to 4.246)	(0.793 to 1.612)
Difference ^b	0.860***	0.849***	1.061***	0.212
	(0.772 to 0.948)	(0.761 to 0.937)	(0.629 to 1.494)	(-0.225 to 0.650)
Observations	222 101	210 181	11 920	222 101
STD (days)				
Without hypertension	2.583	2.367	6.805	4.438***
	(2.485 to 2.682)	(2.290 to 2.444)	(6.073 to 7.537)	(3.750 to 5.126)
With hypertension	6.155	5.801	13.06	7.261***
	(5.846 to 6.464)	(5.518 to 6.084)	(10.81 to 15.31)	(5.048 to 9.475)
Difference ^b	3.572***	3.434***	6.258***	2.824*
	(3.292 to 3.851)	(3.169 to 3.699)	(4.108 to 8.408)	(0.674 to 4.973)
Observations	1 521 915	1 447 756	74 159	1 521 915
LTD (days)				
Without hypertension	0.439	0.441	0.397	-0.0447
	(0.412 to 0.466)	(0.413 to 0.469)	(0.335 to 0.459)	(-0.109 to 0.0198)
With hypertension	0.447	0.451	0.378	-0.0734*
	(0.405 to 0.490)	(0.407 to 0.495)	(0.316 to 0.440)	(-0.138 to -0.00932)
Difference ^b	0.00832	0.00976	-0.0190	-0.0287
	(-0.0322 to 0.0488)	(-0.0323 to 0.0518)	(-0.103 to 0.0651)	(-0.119 to 0.0620)
Observations	1 470 046	1 396 791	73 255	1 470 046
Productivity associated costs^c				
Sick absence costs, \$				
Without hypertension	453.2	440.1	684.8	244.7***
	(445.3 to 461.1)	(432.4 to 447.8)	(637.1 to 732.4)	(197.0 to 292.4)
With hypertension	665.1	649.2	946.1	296.9***
	(639.5 to 690.7)	(623.4 to 675.0)	(820.0 to 1,072)	(169.3 to 424.6)
Difference ^b	211.9***	209.1***	261.3***	52.25
	(184.7 to 239.0)	(181.8 to 236.3)	(126.4 to 396.2)	(-83.98 to 188.5)
Observations	222 101	210 181	11 920	222 101
STD costs, \$				
Without hypertension	444.7	407.5	1172	764.2***
	(432.2 to 457.3)	(397.8 to 417.2)	(1079 to 1265)	(677.0 to 851.4)
With hypertension	1060	998.7	2249	1251***
	(1020 to 1099)	(962.9 to 1035)	(1964 to 2535)	(969.9 to 1531)
Difference ^b	614.9***	591.2***	1078***	486.3***
	(579.6 to 650.3)	(557.7 to 624.8)	(805.0 to 1350)	(213.9 to 758.7)
Observations	1 521 915	1 447 756	74 159	1 521 915
LTD costs, \$				
Without hypertension	97.21	90.79	219.7	128.9
	(-36.18 to 230.6)	(-29.58 to 211.2)	(-213.0 to 652.4)	(-205.8 to 463.6)
With hypertension	281.2	263.3	622.6	359.4

	(-102.9 to 665.2)	(-84.64 to 611.1)	(-677.6 to 1923)	(-686.2 to 1405)
Difference ^b	184.0	172.5	403.0	230.5
	(-70.17 to 438.1)	(-58.48 to 403.4)	(-528.1 to 1334)	(-556.1 to 1017)
Observationss	1 470 046	1 396 791	73 255	1 470 046

Abbreviations: LTD, long-term disability; STD, short-term disability.

*** $Pp < 0.001$, ** $P < 0.01$, * $P < 0.05$.

^a A negative binomial model was used for the number of sick absences and STD. For number of LTD, we used a zero-inflated negative binomial model. A generalized linear model for costs associated with sick absences, STD, and LTD. All estimates were average marginal effects with 95% confidence interval (CI), adjusting patients' age groups, sex, urbanicity of residence, Census regions, and comorbidities. All costs were adjusted to 2021 dollars using the Consumer Price Index from the US Bureau of Labor Statistics.

^b The differences in the predicted values, ie, average marginal effects associated with hypertension.

^c The productivity costs associated with sick absences, STD, and LTD were obtained by multiplying the number of hours of sick absences, STD, and LTD by the average hourly wage in 2020. Adjustments for absences associated with short-term (70% of hourly wage) and long-term (60% of hourly wage) disability were made. The average hourly wage for all employees on private nonfarm payrolls was derived from the US Bureau of Labor Statistics.